Belgium, Netherlands, or Switzerland: Where should your next Life Sciences move take you?

The 2026 market is targeted, not expansive. Companies are still cautious on headcount, but competition for specialist talent in regulatory, quality, manufacturing and clinical roles has tightened sharply, and the balance is shifting back toward candidates with the right profile. Below are four moves that decide whether a cross-border offer is the right one, followed by a side-by-side read on how the three markets compare.

Switzerland, the Netherlands and Belgium are three of Europe's most attractive destinations for life sciences professionals, each offering a different mix of compensation, career opportunities and quality of life. While Switzerland often leads in salaries, the Netherlands combines a strong biotech and MedTech ecosystem with an internationally minded work culture, and Belgium continues to punch above its weight in pharmaceuticals, biologics, and manufacturing.

The 2026 market remains selective rather than expansive. Companies are still cautious about headcount growth, but demand for experienced professionals in regulatory affairs, quality, manufacturing and clinical functions has tightened considerably. For candidates with the right expertise, opportunities remain strong across all three markets.

The question is how to compare them properly. Below are four considerations that should shape any cross-border decision, followed by a side-by-side look at how Switzerland, the Netherlands and Belgium stack up in practice.

A Swiss offer that looks 40% higher can shrink dramatically once you account for where you’ll actually live. Zurich and Geneva are among the most expensive cities on earth, and Switzerland overall runs roughly 17 to 26% pricier than the Netherlands. Housing is where the three markets diverge most, and it isn’t an abstract line item: in Basel, the majority of qualified specialist candidates who decline relocation cite housing costs as the primary reason. Layer in the tax regimes which swing net pay by double digits, and the gross figure on the offer letter tells you very little on its own.

What to do now. Before you compare any two offers, build a simple net model for each: gross, minus income tax, plus the cash value of any expat regime, minus a realistic figure for housing and living costs in that specific city. Compare the bottom lines, not the top lines. A recruiter who works the market daily can hand you the real local housing and tax numbers in an afternoon; guessing them is how people get caught out.

The risk if you don’t. You accept the highest gross of your career, then discover a year and a half in that you have less disposable income than you’d have kept in Leuven or Utrecht and none of the savings you moved for.

This is the move that matters most, and the one candidates skip. Switzerland is the European compensation ceiling, anchored by the big-pharma headquarters in Basel, Roche, Novartis, Lonza and a strong mid-size cluster across the Basel–Zurich–Geneva corridor, with deep, premium demand for HQ-level R&D and, especially, contract specialists in validation, MSAT and CSV. The Netherlands is broader and more biotech-flavoured: the Amsterdam–Leiden–Utrecht cluster plus the Brabant/Oss corridor, with real density in biomanufacturing, MedTech and emerging-therapy scale-up. Belgium is the quiet giant, Europe’s largest pharmaceutical exporter per capita, carrying serious manufacturing and biologics weight at J&J in Beerse, UCB around Brussels and GSK in Wavre, plus a fast-growing biotech base in Flanders.

The critical 2026 nuance is that density is now splitting within hubs, not just between countries. The same city, at the same companies, can be cutting some roles and fighting over others in the same quarter.

What to do now. Before you weigh a single salary figure, list the credible employers for your exact profile in each location, not “pharma in Switzerland” but “sterile-fill GMP leads in the Basel commuter belt” or “operational regulatory professionals fluent across multiple EU jurisdictions.” If your niche gives you thirty employers in one market and three in another, that gap should weigh more heavily than 15% on base.

The risk if you don’t. You take the biggest offer in a city with three employers in your specialism, and buy yourself one good year, followed by a very difficult next move. Over a decade, it’s optionality that protects your earnings, not a single base figure.

Plenty of candidates still talk about expat tax breaks as fixed five-year gifts. They’re not. The Dutch 30% ruling remains useful but is shrinking, while Belgium has quietly become the most generous of the three, a reversal of the usual assumption.

Belgium’s inbound-taxpayer regime now allows up to 35% of gross as a tax-free allowance, the old €90,000 cap has been abolished, and the qualifying salary has dropped to €70,000, all retroactive to January 2025. There is also a separate inbound-researcher track with no salary threshold at all, which matters if you hold a relevant PhD or master’s. The Dutch side moves the other way: the headline allowance steps down from 30% to a flat 27% from January 2027. There has been political talk of restoring the full rate, but nothing is law, which is precisely the point. Switzerland runs no dedicated expat scheme, yet low-tax cantons such as Zug, Schwyz and parts of Zurich keep net pay among Europe’s highest without one.

What to do now. Model your specific situation, not the headline. If you’re eyeing the Netherlands, build the 2027 step-down into your five-year picture rather than today’s rate, and treat any talk of a reversal as noise until it’s enacted. If you’re a researcher considering Belgium, check whether the no-threshold researcher track applies to you before assuming it doesn’t. It’s the kind of detail that quietly changes what offers win.

The risk if you don’t. You anchor on a tax break as it stands today and model a number that shifts underneath you, or you write off a more generous regime next door because its headline salary looked lower.

Language isn’t about ordering coffee; it gates progression. Brussels functions in English, but advancement in Flanders or Wallonia often runs in Dutch or French. The Netherlands is unusually English-friendly at work, with flat hierarchies, short commutes and strong work-life balance. Switzerland is efficient and high-quality but expensive, and work-permit quotas can complicate moves for non-EU candidates. Commute and housing realities differ just as sharply, and they’re a part of a move you live with every single day.

What to do now. Be honest about the language you’ll actually function in day to day, and whether it caps how far you can rise locally. Then factor in the commute and the housing market you’ll really live in, not the relocation-brochure version. And ask the clarifying question: if the salary were identical across all three, which would you genuinely want to live in? That answer is more useful than it looks.

The risk if you don’t. You optimise purely for the offer, land in a role you like inside a life you don’t, and leave within two years which serves neither your earnings nor your CV.

Headline ranges alone don’t tell the story. The point of the table below is how net pay, cost of living, role clustering and lifestyle interact not the largest figure in any one row. Figures are in euros (Swiss francs converted at roughly 1 CHF ≈ €1.08, mid-2026) and are directional bands for senior profiles, not quotes.

The candidates who get cross-border moves right aren’t the ones who find the biggest number. They’re the ones who treat country choice as part of their earnings and their career trajectory, not a relocation-logistics problem to solve after the offer lands. Switzerland, the Netherlands and Belgium are each the best answer for a different person: a different specialism, a different appetite for cost, a different idea of a good life. Run the four moves, and you’ll know which one is yours.